Table 2.
Demographic and clinical characteristics of HIV+ diffuse large B-cell lymphoma cases by EBV status.
| EBV-negative (N=48) | EBV-positive (N=22) | p-value | |
|---|---|---|---|
| Age (years), mean (sd) | 47.9 (9.3) | 49.6 (9.5) | 0.49 |
| Male gender, n (%) | 45 (93.8%) | 19 (86.4%) | 0.37 |
| Race/Ethnicity, n (%) | |||
| White | 28 (58.3%) | 13 (59.1%) | 0.20 |
| Black | 9 (18.8%) | 2 (9.1%) | |
| Hispanic | 11 (22.9%) | 5 (22.7%) | |
| Asian/Pacific islander | 0 (0%) | 2 (9.1%) | |
| Stage, n (%) | |||
| I (Localized) | 11 (22.9%) | 5 (22.7%) | 0.89 |
| II (Regional) | 8 (16.7%) | 4 (18.2%) | |
| III (Distant) | 25 (52.1%) | 10 (45.5%) | |
| Extranodal involvement, n (%) | |||
| Single site involvement | 12 (25.0%) | 6 (27.3%) | |
| ≥2 sites on the same side of the diaphragm | 9 (18.8%) | 4 (18.2%) | |
| Both sides of the diaphragm | 4 (8.3%) | 4 (18.2%) | 0.36 |
| Disseminated | 23 (47.9%) | 7 (31.8%) | |
| Subtype, n (%) | |||
| Centroblastic | 38 (79.2%) | 13 (59.1%) | 0.10 |
| Immunoblastic | 8 (16.7%) | 5 (22.7%) | |
| Plasmablastic | 2 (4.2%) | 4 (18.2%) | |
| Germinal center phenotype, n (%) | 22 (47.8%) | 5 (22.7%) | 0.06 |
| Detection of LMP1, n(%) | NA | 8 (36.4%) | NA |
| Elevated serum lactose dehydrogenase, n (%) | 25 (69.4%) | 14 (73.7%) | 0.74 |
| ECOG performance status ≥2, n (%) | 9 (20%) | 4 (20%) | 1.00 |
| Presence of B symptoms n (%) | 11 (22.9%) | 8 (36.4%) | 0.35 |
| International prognostic index, n (%) | |||
| 0–1 (low risk) | 11 (32.3%) | 7 (41.2%) | |
| 2 (low-intermediate risk) | 7 (20.6%) | 4(23.5%) | 0.91 |
| 3 (high-intermediate risk) | 11 (32.3%) | 4 (23.5%) | |
| 4–5 (high risk) | 5 (14.7%) | 2 (11.8%) | |
| Chemotherapy, n (%) | 42 (87.5%) | 16 (72.7%) | 0.17 |
| CHOP | 20 (47.6%) | 8 (50.0%) | |
| RCHOP | 15 (35.7%) | 4 (25.0%) | 0.36 |
| Other | 2 (4.8%) | 3 (18.8%) | |
| HIV risk group, n (%) | |||
| Heterosexual | 9 (18.8%) | 6 (27.3%) | 0.83 |
| Intravenous drug user | 1 (2.1%) | 0 (0%) | |
| Men who have sex with men | 22 (45.8%) | 9 (40.9%) | |
| Other/Unknown | 16 (33.3%) | 7 (31.8%) | |
| Known HIV duration (years), mean (sd) | 6.2 (6.2) | 3.1 (4.0) | 0.06 |
| Prior AIDS diagnosis, n (%) | 19 (39.6%) | 12 (54.6%) | 0.24 |
| Prior use of cART, n (%) | 29 (60.4%) | 16 (72.7%) | 0.32 |
| CD4 at diagnosis (cells/mm3), mean (sd) | 247.9 (169.0) | 128.4 (132.3) | 0.01 |
| CD4 lowest KP recorded (cells/mm3), mean (sd) | 85.7 (72.2) | 43.8 (42.5) | 0.02 |
Percentage may not add up to 100% due to missing values.